Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
Amgen's blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared...
Pharmaceutical companies sponsoring clinical trials showed strong improvement in their...
Takeda Pharmaceutical Company Limited announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients.
GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases.
Sucampo Pharmaceuticals has announced that it signed an amendment to the existing collaboration and license agreement covering the United States and Canada for AMITIZA with Takeda Pharmaceutical Company.
Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, today announced that the FDA has approved VELCADE® for injection for use in previously untreated patients with mantle cell lymphoma. VELCADE is the first treatment in the United States to be approved for use in previously untreated patients with MCL.
Takeda Pharmaceuticals International has announced that John Boslego, MD, has been named Senior Vice President and Head of Development for Takeda’s Global Vaccine Business Unit, effective December 1, 2014.
Takeda Pharmaceutical has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda's diabetes medicine Actos.
Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, has announced that the FDA has approved VELCADE® for the retreatment of adult patients with multiple myeloma who had previously responded to VELCADE therapy and relapsed at least six months following completion of prior VELCADE treatment.
New Takeda Pharmaceutical Company President Christophe Weber said recently that Japan's biggest drugmaker will continue efforts to expand its business abroad through acquisitions and will outline a new strategy by the end of the year.
A group of shareholders, led by Yujiro Hara, opposes the hiring of foreign executives at Takeda Pharmaceutical, the biggest drug company in Japan, calling it a “hijacking by foreign capital.”
MacroGenics and Takeda jointly announced today that they have entered into an option agreement for the development and commercialization of MGD010. Under the terms of the agreement, MacroGenics will receive an upfront payment of $15M and Takeda receives an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.
Today's verdict marks the fifth win for Takeda out of six ACTOS (pioglitazone HCL) trials. Takeda is challenging the ruling in the sixth case.
Takeda Pharmaceuticals U.S.A., Inc., today announced that the FDA simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
A state senator cannot sue for defamation over a rival's campaign ad that misleadingly suggested he sold dangerous drugs to children, the Iowa Supreme Court ruled Friday in a case that could have implications for politics nationwide.
Takeda Pharmaceuticals U.S.A. announced that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois and is the fifth ACTOS (pioglitazone HCl) case to reach trial.
Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan.
Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.
Takeda Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. market.
Takeda Pharmaceuticals International GmbH today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.
Sucampo Pharmaceuticals, Inc. (SPI) today announced that it has received a $10 million milestone payment from Takeda Pharmaceutical Company Limited (Takeda), pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA ® (lubiprostone) in the United States for the treatment of opioid-induced constipation (OIC) in adult patient.
Takeda Pharmaceutical Company’s Chief Executive Officer Yasuchika Hasegawa talks to the Wall Street Journal about his management style and “Takeda-ism” – the corporate philosophy that has led Takeda to becomeJapan’s biggest pharmaceutical manufacturer.
Dr. Peter C. Butler initially declined a request by the drugmaker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats. “I said, I’m not interested in your money, go away,” Butler recalled. Merck no doubt now wishes it had.
Amag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland. Amag said four patients experienced severe allergic reactions to the drug, and one of those patients died. That batch was sold only in Switzerland, and the recall doesn't affect any other countries.
Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.
Takeda Pharmaceuticals International GmbH, today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. will be headquartered in Quito and will be responsible for the sales and marketing of Takeda's products in Ecuador.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
- Page 1